May 24, 2016 / 11:27 AM / a year ago

BRIEF-Theratechnologies says 82.5 pct patients achieved primary endpoint in Phase III ibalizumab trial

1 Min Read

May 24 (Reuters) - Theratechnologies Inc

* Theratechnologies announces that 82.5% of patients achieved the primary endpoint in the phase III ibalizumab trial

* Says taimed plans to submit an abstract to present these results at a major scientific conference later this year Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below